BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37483544)

  • 1. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Zhang Y; Yan B; Shen S; Song X; Jiang Y; Shi L; Zhao C; Yang Y; Jiang L; Li J; Ye J; Liu J; Wan L; Yang Y; Chen J; Liu F; Su L; Xu Y; Tan G; Yu S; Zhang Y; Wang L; Liu S; Yan H; Liu W; Chen B; Wang C; Zhang L
    EClinicalMedicine; 2023 Jul; 61():102076. PubMed ID: 37483544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.
    Zhang Y; Yan B; Zhu Z; Wang X; Song X; Zhu D; Ma T; Zhang Y; Meng C; Wang G; Wang C; Zhang L
    EClinicalMedicine; 2024 Mar; 69():102467. PubMed ID: 38356731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han JK; Bachert C; Fokkens W; Desrosiers M; Wagenmann M; Lee SE; Smith SG; Martin N; Mayer B; Yancey SW; Sousa AR; Chan R; Hopkins C;
    Lancet Respir Med; 2021 Oct; 9(10):1141-1153. PubMed ID: 33872587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
    Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER
    JAMA; 2016 Feb; 315(5):469-79. PubMed ID: 26836729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
    Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
    Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
    J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
    Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
    J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
    Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
    Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.
    Zhao Y; Zhang J; Yang B; Li J; Ding Y; Wu L; Zhang L; Wang J; Zhu X; Zhang F; Tao X; Li Y; Zhang C; Li L; Lu J; Diao Q; Lu Q; Man X; Li F; Xia X; Cheng H; Jia Y; Zhao G; Yan J; Chen B
    Chin Med J (Engl); 2024 Jan; 137(2):200-208. PubMed ID: 37482623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
    Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
    Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
    Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mometasone furoate nasal spray in the treatment of nasal polyposis in Chinese patients: a double-blind, randomized, placebo-controlled trial.
    Zhou B; He G; Liang J; Cheng L; Mehta A; Liu S; Yu W; Wang Z; Han D
    Int Forum Allergy Rhinol; 2016 Jan; 6(1):88-94. PubMed ID: 26575524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
    Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
    Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial to evaluate mometasone lavage vs spray for patients with chronic rhinosinusitis without nasal polyps who have not undergone sinus surgery.
    Jiramongkolchai P; Peterson A; Kallogjeri D; Lee JJ; Kukuljan S; Liebendorfer A; Schneider JS; Klatt-Cromwell CN; Drescher AJ; Piccirillo JF
    Int Forum Allergy Rhinol; 2020 Aug; 10(8):936-943. PubMed ID: 32470217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
    Tversky J; Lane AP; Azar A
    Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
    Hopkins C; Wagenmann M; Bachert C; Desrosiers M; Han JK; Hellings PW; Lee SE; Msihid J; Radwan A; Rowe P; Amin N; Deniz Y; Ortiz B; Mannent LP; Rout R
    Int Forum Allergy Rhinol; 2021 Jul; 11(7):1087-1101. PubMed ID: 33611847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
    Sindwani R; Han JK; Soteres DF; Messina JC; Carothers JL; Mahmoud RA; Djupesland PG
    Am J Rhinol Allergy; 2019 Jan; 33(1):69-82. PubMed ID: 30477309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.